Biotech News

GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

GSK plc (GSK)gsk.com2026-06-12 06:09 ESTClinical readout

ATLAS phase II/III trial in VEXAS underway, advancing momelotinib’s broader development programme.

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

GSK plc

GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NYSE
Sector
Biotechnology
Location
United States